BridgeBio Pharma Inc. has gained approval from the US Food and Drug Administration for its new heart medication, Attruby. This medication is intended to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a severe and progressive heart disease.

The approval allows BridgeBio to enter the market for treatments targeting this condition, where it will directly compete with Pfizer Inc. Attruby will be priced at $18,759 for a 28-day supply, reflecting the high costs associated with innovative therapies in the pharmaceutical industry.

This approval is a significant milestone for BridgeBio as it aims to establish itself in a competitive landscape that is currently dominated by established players such as Pfizer.